PharmaMar

Executive Summary

PharmaMar is a Spanish biopharmaceutical company pioneering marine-derived anticancer drugs. With three commercial products, including Yondelis (trabectedin) for soft tissue sarcoma, the company also has a pipeline of novel candidates targeting oncology. Key assets include lurbinectedin (Zepzelca), approved in the US for small cell lung cancer, and plitidepsin, in development for multiple myeloma and COVID-19. The company leverages its proprietary marine platform to discover unique small molecules. Financially, PharmaMar generates revenue from product sales and partnerships, though profitability remains a challenge due to R&D investment. Upcoming catalysts include pivotal trial readouts for plitidepsin in hematologic malignancies and potential label expansions for lurbinectedin. With a focused pipeline and established commercial foothold, PharmaMar is positioned for growth but faces competition from other oncology therapies.

Upcoming Catalysts (preview)

• Q3 2026Plitidepsin Phase 3 results in multiple myeloma60% success
• Q1 2026Lurbinectedin FDA decision for second-line small cell lung cancer70% success
• Q4 2025New marine-derived compound entering Phase 1/2 trials80% success